INDEX

Note: Italicized b, f and t refer to boxes, figures and tables

3,4-dihydroxyphenylacetic acid (DOPAC), 226
5-hydroindoleacetic acid (5-HIAA), 154, 226
5-hydroxytryptophol (5-HTOL), 154
6-acetylmorphine, 151

abuse, definition of, 7b
accounts, 66–67, 66b
acetaldehyde adducts, 155
active comparators, 49–50
addiction
cost of, 359b
definition of, 7b
outcomes, 359b
addiction gene, 263
addiction research, 1–4
ethical issues in, 83–87
administering addictive drugs, 86–87, 86b
anonymity, 87
appropriate funding sources, 88–89
autonomy/rational choice, 85
confidentiality, 87
informed consent, 83–84
subject payment, 84–85
vested interests, 88–89
initial stages, 1–2
literature review in, 3–4
methods, 4
neuroimaging and, 240–241
overview, 1
questions, 2–3
reliability, 11–24
study design in, 8
theory, 2
types of variables measured in, 18f
validity, 11–24
Addiction Research Center Inventory (ARCI)
questions, 227b
addiction service delivery, audit of, 189b
Addiction Severity Index (ASI), 118, 130, 133–135
addiction treatment services, organisational function
testing in, 195b
addictive drugs, administration of, 86–87, 86b
adenine, 249
adoption studies, 255–256
agent-based models (ABMs), 366
Alcohol and Drug Survey and Illicit Drug Monitoring System, 98
alcohol metabolism, 261f
alcohol taxes, 355–356
alcohol treatment studies, 51b
Alcohol Use Disorders Identification Test (AUDIT), 128
alcohol-use research. See also addiction research
consumption and cirrhosis mortality, 305f
epidemiology and, 300
measurements in, 20b
aldehyde dehydrogenase 2 (ALDH2), 262b
allelic association, 260f
amphetamines, 152
analysis, 70–73
descriptive thematic, 71–72
discourse, 73
grounded theory, 72–73
narrative, 73
qualitative, 70–71, 71b
analysis of variance (ANOVA), 55, 174
animal models, 269–281
adjunct procedures, 281
behavioural and neuroscience techniques in, 281
conditioned place preference, 278–279
drug discrimination, 279, 280f
drug self-administration, 270–278
environmental cues, 270
locomotor activity, 279
overview, 269
reinforcement, 269–270
in translational research, 203
animal studies, 252–254
anonymity, 80, 87, 195
anterior cingulate (ACC), 240–241
applied research methods, 187–198
audit cycle, 197
clinical audit, 189–190
evaluation research, 193–197
measuring outcomes in applied settings, 197–198
needs assessment, 190–192
overview, 187–188
qualitative methods, 192–193
reasons to use, 187–188
arrays, 260
arterial spin labeling, 240
association, 259–261
Association for Assessment and Accreditation of Laboratory Animal Care International, 203
Index

attrition, 330
audit cycle, 197
autonomy, 80, 85
axial coding, 73, 293–294
Beck Depression Inventory (BDI), 139–140
behaviour. See also animal models
environmental cues, 270
reinforcement, 269–270
behavioural economics analysis, 273
behavioural sensitisation, 279
beneficence, 80, 88
benzoylecgonine, 148, 149t, 151
Bergen earlier warning system (BEWS), 340f
between-group designs, 45–47
bias, 28t
binomial effect size display, 326–327
biochemical markers, 111
biomarkers, 147–156
accuracy of reported substance abuse with, 147–148
for alcohol use, 152–156
for drug use, 151–152
factors in choice of, 150t
general principles, 149–151
overview, 147
urine screening and, 148
Birmingham Treatment Effectiveness Initiative, 187
blood alcohol level (BAL), 113
blood analysis, 151
blood liver function tests, 229
blood plasma, 224–225
blood-brain barrier, 225b
bogus pipeline effect, 111
Bonferroni correction, 55
Brief Symptom Inventory (BSI), 139–140
Brief intervention, see Screening and brief interventions (SBI)
CAGE, 118, 128–129
cannabinoids, 152
cannabis, 263b
carbohydrate-deficient transferrin (CDT), 154
case-control studies, 16, 307, 308–310
case-crossover studies, 306–307
catechol-O-methyltransferase, 263b
Celera Genomics, 251
Census Bureau, 97–98
Center for Substance Abuse Treatment (CSAT), 211
chance, 45
chat room interviews, 117–118
Chicago School ethnography, 288
childhood sexual abuse, 263b
choice procedure, 273
chromosomes, 257f
classical test theory, 12
clinical audit, 189–190
Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar), 231b
clinical interviews, 112–113
clinical research, 201–216
costs, 210
efficacy vs. effectiveness studies, 208t
evidence pyramid, 202f
evidence-based practices, 210, 210–211
overview, 201–202
phase 1, 203–204
phase 2, 203–204
phase 3, 205–206
phase 4, 208
public health, 210
randomised controlled trials, 205–206
role of practitioner-researchers, 211–212
translational, 202–203
treatment systems, 210
utilisation patterns, 210
clinical trials, 310
cluster, 28t
cluster sampling, 31–32, 33b, 38t
cluster-randomised between-group designs, 46
cocaine, 151, 272f
coding, 321
cohort studies, 16–17, 99, 307, 308–310
cold calling, 290–291
cold canvassing, 290–291
Collaborative Studies on Genetics of Alcoholism, 259
collateral interviews, 118–119
COMBINE study, 148b
communitarian ethics, 81–82
Composite International Diagnostic Instrument (CDI), 141
Composite International Diagnostic Instrument – Substance Abuse Module, 136–137
Comprehensive Drinker Profile (CDP), 133–134
counter-assisted self-interviewing (CASI), 39, 120
Computer-Assisted Survey Execution System, 39
counter-assisted surveys, 39
counterised interviews, 117
counter validity, 15
counter locomotion, 279
counter place preference, 278–279
counter reinforcer, 270
counter sensitisation, 279
counter stimuli, 270
counter intervals, 170–171, 311–312
counter validity, 15
counter management (CM) treatment, 205b
counter, 45
counter condition, 45
counter validity, 15, 349
convergent validity, 15, 349
conversational interviews, 104
correlation coefficient, 322
cost-benefit analysis, 338
cost-effectiveness analysis, 357
cost-identification analysis, 356
cost-offset analysis, 356–357
cost-utility analysis, 358
coverage, 346
crack cocaine, 151
craving measures, 232
creatinine, 149
Crick, Francis, 249, 251, 252
Criterion sampling, 37
criterion-related validity, 15
critical case sampling, 37
critical realism, 61–62
cross-sectional studies, 16, 305–306
CSA Illumina Databases, 3
cue-induced reinstatement, 275
cytosine, 249
data, 168–171
certainty intervals, 170–171
goodness of fit, 169–170
kurtosis, 168
mean, 168
median, 168
mode, 168
skew, 168–169
variance, 168
data collection, 165, 195
data entry programmes, 120
data generation, 64–70
diaries, 70
documents, 69–70
group interviews, 67
interviews, 64–67
observation, 67–68
visual data, 68–69
data reduction, 172
databases, 3–4
decision-making models, 82–83
deduction, 2b, 3f, 59–60
deoxyribose nucleic acid (DNA), 249, 251, 252
dependence scales, 135–139
Composite International Diagnostic Instrument – Substance Abuse Module, 136–137
Leeds Dependence Questionnaire, 137
Severity of Alcohol Dependence Questionnaire, 138
Severity of Dependence Scale, 137–138
Severity of Opiate Dependence Questionnaire (SODQ), 139
Short Alcohol Dependence Data (SADD), 135–136
dependent variable, 45
descriptive epidemiology, 300–301, 303–304
descriptive thematic analysis, 71–72
diagnostic case sampling, 36
diagnostic interviews, 118
difference-in-differences, 364–365
diffusion tensor imaging, 240
digital recordings, 120
disconfirming case sampling, 37
discriminant validity, 15
discriminative stimulus, 270
distributive justice, 80
dizygotic twins, 255
DNA chips, 260
DNA extraction, 256
DNA markers, 256–257
DNA sequencing gel, 253
documents, See Documentary data, 69–70
dopamine, 226
Dose-effect functions, 271, 272
double-barreled questions, 102
Drug Abuse Screening Test (DAST), 129
drug classification, 341
drug concentration, 224–226
drug discrimination, 279, 280
Dose-effect functions, 271, 272
drug effects, 226–278
blood liver function tests, 229
cardiorespiratory measures, 228
measurement of, 226–229
neurophysiological testing, 228
objective measures of, 227–228
physiological assessment, 228
subjective, 227–228
drug policy research, 355–366
definition of, 355
economic vs. accounting costs, 361
methods, 362–366
modelling, 365–366
quasi-experimental, 363–365
randomised controlled trials, 362–363
metrics, 356–358
cost-benefit analysis, 358
cost-effectiveness analysis, 357
cost-identification analysis, 356
cost-offset analysis, 356–357
cost-utility analysis, 358
perspective, 360–361
sin taxes, 355–356
time horizon, 361–362
drug priming, 275
drug research, epidemiology and, 300
drug seizures and law enforcement data, 343–344
drug self-administration, 229–231
addiction modelling, 275–276
advantages/disadvantages of, 278
context dependence of, 204
Dose-effect functions, 271, 272
effect on, 230
environmental cues, 273–275
food-reinforced responding and, 281
intracranial, 276–278
locomotor activity and, 281
methods, 229
outcomes, 230–231
positive ratio schedule, 273
positive reinforcement and, 269
reinforcing effects of drugs, 271–273
Index

drug self-administration (cont.)
- reinstatement, 275, 275f
- second-order schedules, 273
- sedative, 230b
- simple schedules, 270–271
- drug specificity, 346
- drug trend monitoring, 337–349
- challenges in, 339–341
- data analysis and interpretation, 345–347
- information sources, 341–344
- drug seizures and law enforcement data, 343–344
- household surveys, 343
- informant panels and surveys, 343–344
- school surveys, 342
- treatment and health data, 343
- international/national/local levels, 338–339
- issues in, 337–338
- mixed methods, 345–346
- overview, 337
- reliability and validity, 348–349
- triangulation, 347–348
- drug use, laboratory markers for, 151–152
- drug withdrawal syndromes, 231–232
- Dunedin longitudinal study, 263b

- ecological fallacy, 304, 305b
- ecology data analysis, 304
- efficacy studies, 208t
- efficacy studies, 208t
- electroencephalographs (EEGs), 228
- eligibility criteria, 51b, 320
- email surveys, 100
- endophenotypes, 257
- environmental cues, 273–275
- epidemiology, 299–315
- alcohol-use research and, 300
- case-control studies, 306, 308–310
- case-crossover studies, 306–307
- cohort studies, 307, 308–310
- cross-sectional studies, 305–306
- descriptive, 300–301, 303–304
- drug research and, 300
- ecology data analysis, 304
- experimental, 301, 310
- observational, 301
- origins of, 299
- research design, 301–303
- risk ratios vs. odd ratios, 310
- routine data analysis, 304
- secondary data analysis, 304
- sources of errors in, 311–314
- confounding, 313–314
- measurement bias, 313
- random error, 311
- sample bias, 312–313
- sample size, 311–312
- systematic error, 312
- study designs, 303t
- epigenetics, 261–262
- equal allocation, 28t
- EtG marker, 153–154, 156
- ethanol, 152–153
- ethical dissemination, 89
- ethics application, 85
- ethics committees (ECs), 80, 87–88
- ethics in research, 79–89
- addiction-specific issues, 83–87
- administering addictive drugs, 86–87, 86b
- anonymity, 87
- autonomy/rational choice, 85
- confidentiality, 87
- informed consent, 83–84
- subject payment, 84–85
- anonymity, 80
- communitarian ethics, 81–82
- confidentiality, 80
- decision-making models, 82–83
- ethical dissemination, 89
- ethics application, 87
- ethics processes in different countries, 87–88
- genetics research, 264
- influence of funding body, 88–89
- informed consent, 79
- overgrowth syndromes, 79
- PERIL framework, 88–89
- principlism, 80–81
- universal values, 81b
- voluntary participation, 79
- ethics officer, 85
- Ethnograph, 39
- ethnographic drug research, 287–295
- data analysis, 293–294
- data collection, 292–293
- designing, 289–290
- field, 290–291
- history of, 288–289
- literature review, 290
- overview, 287–295
- participants, 291
- sampling, 291–292
- writing up findings, 294–295
- ethnographic mapping, 291–292
- ethnography, 67–68, 287
- ethyl glucuronide, 148
- EtP marker, 154
- EtS marker, 153–154
- European early warning system (EWS), 345b
- evaluation research, 193–197
- anonymity and data collection, 195
- implications, 196–197
- model, 194b
- purpose of, 193
- recruitment and representativeness, 195–196
- stages, 194
- evidence pyramid, 202f
- evidence-based practices (EBPs), 210–211
- evidentiary pluralism, 211
- Expanded Academic database, 3
- experimental designs, 43–56
- active comparators, 49–50
between-group designs, 45–47
  cluster-randomised, 46
  fractional factorial designs, 47
  individually randomised, 45–46
  preference design, 47
  randomised content design, 47
  stepped wedge design, 46
in epidemiology, 310
intervention/control conditions, 48–49
outcome measures, 53–55
recruitment strategy, 50–52
sample size, 52
statistical analyses, 55–56
target population, 50–52
within-subject designs, 47–48
experimental epidemiology, 301, 310
experiments, 43–56
  appropriate, 44
  overview, 43–44
extent of funding, 88–89
external validity, 16, 349
extreme case sampling, 36

F ratio, 168
face-to-face interviews, 117
faking data, 19
familiar recurrence risk, 254
family studies, 254
Fast Alcohol Screen Test (FAST), 118
fatty acid ethyl esters (FAEEs), 153–154, 156
focus groups, 67, 117
follow-up, 53, 54
Food and Drug Administration (FDA), 203
food-reinforced responding, 281
formal theory, 72–73
fractional factorial designs, 47
framework analysis, 71–72
Franklin, Rosalind, 252
frequency of substance use, 130–132
Addiction Severity Index, 130
Opiate Treatment Index, 131
Franklin, Rosalind, 252
frequency of substance use, 130–132
Addiction Severity Index, 130
Opiate Treatment Index, 131
framing of substance use, 130–132
Addiction Severity Index, 130
Opiate Treatment Index, 131
timeline follow-back method, 132
Focus Group, 72–73
functional magnetic resonance imaging (fMRI), 239
funding bodies, influence of, 88–89
funnel plots, 325
gamma-glutamyltransferase (GGT), 154
gene-envioironment interaction, 262–263
General Health Questionnaire (GHQ), 141–142
generalsability, 287
Genetics, 249–265
addiction gene, 263
animal studies, 252–254
ethics, 264
history, 249–250
lethal genes, 264b
molecular, 256–263
overview, 249
quantitative, 254–256
  adoption studies, 255–256
  family studies, 234
  segregation analysis, 255
  twin studies, 255
Global Appraisal of Individual Needs (GAIN), 118
goodness of fit, 169–170
grounded theory, 72–73, 289
guanine, 249
Hair analysis, 151, 155–157
Hawthorne effect, 49
heritability, 254
heroin, 151
heterogenous population, 28
hidden population, 28
homogeneity test, 323
homogenous population, 28
homovanillic acid (HMA), 226
homozygous sampling, 37
household surveys, 343
identical twins, 255
image generation, 240
image processing, 240
imaging, 235–244
  addiction research and, 240–241
  analysis, 241–244
  arterial spin labeling, 240
  diffusion tensor imaging, 240
  endogenous neurotransmitter release, 236
  factors in setting up, 244
  functional magnetic resonance imaging (fMRI), 239
  overview, 235
  pharmaco-MRI, 240
  positron emission tomography, 235–236
  pros and cons of, 237
  single photon emission computed tomography, 235–236
  structural magnetic resonance imaging, 237–239
imaging study, 235–244
  addiction research and, 240–241
  analysis, 241–244
  arterial spin labeling, 240
  diffusion tensor imaging, 240
  endogenous neurotransmitter release, 236
  factors in setting up, 244
  functional magnetic resonance imaging (fMRI), 239
  overview, 235
  pharmaco-MRI, 240
  positron emission tomography, 235–236
  pros and cons of, 237
  single photon emission computed tomography, 235–236
  structural magnetic resonance imaging, 237–239
implementation checks, 54
incidence, 301
independent variable, 45
in-depth interviews, 65–66, 65b
individually randomised between-group designs, 45–46
induction, 26, 59–60
informant panels and surveys, 343–344
information sources, 342–344
drug seizures and law enforcement data, 343–344
household surveys, 343
informant panels and surveys, 343–344
school surveys, 342
treatment and health data, 343
informed consent, 79, 83–84
instant messaging interviews, 117–118
institutional review boards (IRBs), 80
instrumental variables, 363–364
instruments, 127–143
dependence, 133–139
frequency of substance use, 130–131
multi-dimensional scales, 133–135
psychopathology, 139–143
screening, 128–130
self-report, 127
intensity sampling, 36
intent-to-treat analysis, 330
interaction terms, 55
internal validity, 16, 349
International Human Genome Mapping Consortium, 251
internet surveys, 39, 100
interpretivism, 59
interval variables, 164, 174, 175–176
intervention conditions, 48–50
intervention groups, 45
interviewees, difficult, 115–116
interviews, 109–121
accounts, 66–67, 66b
advantages of, 110b
characteristics of, 111
collateral, 118–119
concerns in using, 110b
conversational, 104
data generation with, 64–67
diagnostic, 118
disadvantages of, 110
face-to-face, 117
focus groups, 67
group, 67
in-depth, 65–66, 65b
indicated population, 119t
method of administration, 117–118
natural groups, 67
non-directive, 65–66
overview, 109
psychometric properties, 119t
reasons to use, 109
respondent characteristics, 112
screening, 118
self-reported data, 110–111
semi-structured, 65, 104, 116
skills, 112–116
clinical interviewing, 112–113
culturally appropriate interviews, 114–115
difficult interviewees, 115–116
rapport building, 113–114
research interviewing, 112–113
research setting, 114
standardised, 104
structured, 64–65
technological resources, 120
computer-assisted self-interviews, 120
digital recordings, 120
optical scanning systems, 120
real-time data entry programmes, 120
types of, 104–105
formats, 116, 117b
method of administration, 117
types of data, 118–120
unstructured, 104, 116
intracranial drug self-administration, 276–278
intracranial self-stimulation, 276–278
JSTOR, 3
kurtosis, 169
Leeds Dependence Questionnaire (LDQ), 137
leptokurtic data, 169
lethal genes, 264b
linkage analysis, 254, 258–259
literature review, 3–4
locomotor activity, 279
longitudinal surveys, 99
loss to follow-up, 54
lung cancer, 302b
Lung Health Study, 45b
lysergic acid diethylamide (LSD), 152
magnetic resonance imaging (MRI), 237–239, 237t
masking, 28t
Maudsley Addiction Profile (MAP), 134
maximum variation sampling, 36
mean, 168
mean corpuscular volume (MCV), 154
measurement, 18–19, 21–24
measurement bias, 312, 313
measurement score, 12
median, 168
Mendel, Gregor Johann, 250b
meta-analysis, 319–332
of addiction interventions, 327–331
attrition, 330
between- and within-group effect sizes, 329–330
comparison conditions, 328
follow-up point, 329
individual- vs. group administered, 328–329
methodological quality, 330–331
multiple outcome variables, 328–329
participant characteristics, 327
aggregated effect sizes across studies, 323
coding decisions in, 321
definition of, 319
effect sizes within studies, 321–323
eligibility criteria, 320
limitations of, 331
moderator variables, 323–324
overview, 319–320
publication bias, 325–326
relevant studies, 321
reports, 326–327
research questions, 320
statistical power of, 324–325
study eligibility criteria, 320
methamphetamine, 152
methylenedioxymethamphetamine (MDMA), 152
Michigan Alcohol Screening Test (MAST), 129–130
microsimulation models, 365–366
mode, 168
modelling methods, 365–366
moderator variables, 323–324
molecular genetics, 256–263
association, 259–261
DNA extraction, 256
DNA markers, 256–257
endophenotypes, 257
epigenetics, 261–262
gene-environment interaction, 262–263
linkage analysis, 258–259
quantitative data trait loci, 257
Monitoring the Future Survey, 98
monoamine oxidase A gene, 263b
monozygotic twins, 255
morphine, 151
multi-dimensional scales, 133–135
Addiction Severity Index (ASI), 133
Comprehensive Drinker Profile, 133–134
Maudsley Addiction Profile, 134
Opiate Treatment Index (OTI), 134–135
naltrexone implants, 82b
narrative analysis, 73
National Alcohol Survey, 98
National Epidemiologic Survey on Alcohol and Related Conditions, 98
National Institute on Alcohol Abuse and Alcoholism, 98
National Longitudinal Alcohol Epidemiologic Survey, 98
National Survey on Drug Use and Health, 98
natural groups, 67
needs assessment, 190–192
negative questions, 102–103
negative reinforcement, 270
neurotransmitter functions, 224–226
New England Regional ATTC, 211
nicotine replacement therapy (NRT), 50
N-of-1 designs, 47–48
nominal variables, 164, 173, 174
non-directive interviews, 65–66
non-identical twins, 255
non-maleficence, 80
non-oxidative ethanol metabolites, 153–154
non-probability sampling, 27, 32
non-response, 28t
NVIVO, 39
objectivity, definition of, 14b
observation, 67–68
observational epidemiology, 301
observational studies, 16
odds ratios, 310, 322
online interviews, 117–118
open coding, 293
opiate addiction, 61b
Opiate Treatment Index (OTI), 131, 134–135
opiates, 151
optical scanning systems, 120
optimal allocation, 28t
orbitofrontal cortex (OfCx), 240–241
ordinal variables, 164, 174
outcome measures, 53–55
outcome variable, 11
oversampling, 28t
PAIS, 3
panel studies, 99
parallel-test reliability, 14
Parkinson’s disease, 226b
participant observation, 292
participants in research, 291
PERIL framework, 88–89
periodicity, 28t
pharmacodynamics, 224b
pharmacokinetics, 224b
pharmaco-MRI, 240
Philosophical Transactions, 3
phosphatidylethanol, 155
Pigouvian tax, 355
plutocratic data, 169
disjunctive data, 169
polarity, 225b
positive ratio schedule, 273, 274f
positive reinforcement, 269
positivism, 59
positron emission tomography (PET), 235–236, 237t, 243b
post-stratification, 28t
practitioner-researchers, 211–212
pre-clinical research, 203
predicting variable, 11
predictive validity, 15
preference design, 47
premature death, 359b
prevalence, 300
preventive trials, 310
primary sampling unit, 28t
principlism, 80
probabilistic atlas, 241
probability proportional to size, 28t
probability sampling, 27, 27–29
process measures, 34
Project MATCH, 207b
Project TrEAT (Trial for Early Alcohol Treatment), 209b
propensity scores, 363–364
property crimes, 359b
proportional allocation, 28t
prospective cohort study, 307
psychopathology scales, 139–143
Back Depression Inventory, 139–140
Brief Symptom Inventory, 139–140
Composite International Diagnostic Instrument, 141
General Health Questionnaire, 141–142
Social Functioning 12, 142
State Trait Anxiety Index Inventory, 142–143
psychopharmacology, 223–232
aims of, 223–224
craving measures, 232
drug concentration and neurotransmitter changes in, 224–226
drug effect measurements, 226–229
drug self-administration, 230–231
drug withdrawal syndromes, 231–232
overview, 223
psychosis, 226b, 263b
PsychInfo, 3
public health, 210
publication bias, 325–326
PubMed, 3
purpose of research, 88
purposive sampling, 291
qualitative analysis, 70–71, 71b
qualitative research, 59–74
analysis, 70–73
descriptive thematic, 71–72
discourse, 73
grounded theory, 72–73
narrative, 73
qualitative, 70–71, 71b
applied research, 192–193
data generation, 64–70
diaries, 70
documents, 69–70
group interviews, 67
talks, 64–67
observation, 67–68
visual data, 68–69
methods, 73–74
principles for practice, 63–64, 63b
vs. quantitative research, 62
techniques, 59, 74
deduction vs. induction, 59–60
positivism vs. interpretivism, 59
realism vs. critical realism, 61–62
qualitative sampling, 27, 36–37, 38t
quality control, 19
quantitative data analysis, 163–178
data cleaning, 167
data collection, 165
data description, 167–171
confidence intervals, 170–171
goodness of fit, 169–170
kurtosis, 169
mean, 168
median, 168
mode, 168
skew, 168–169
variance, 168
data manipulation, 171–173
calculated variables, 173
data reduction, 172
shape of distribution, 173
data structure, 166–167
errors in significance testing, 175–176
measurement levels, 164–165
overview, 163
pilot study, 163–164
relationships within data, 173–176
interpretation, 177–178
between multiple interval and ratio measures, 175–176
between nominal and ordinal measures, 174
between nominal level measures, 173
between nominal or ordinal and interval or ratio measures, 174–175
between types of measures, 173
statistical packages, 166
quantitative genetics, 254–256
adoption studies, 255–256
family studies, 254
segregation analysis, 255
twin studies, 255
quantitative research, vs. qualitative method, 62
quantitative trait loci, 258
quantity frequency (QF), 131–132
quasi-experimental methods
difference-in-differences, 364–365
instrumental variables, 363–364
propensity scores, 363–364
regression discontinuity, 365
Questionnaire Development System, 39
questionnaires, 101–105
pilot testing, 104–105
question development, 101–103
ability to answer, 102
analysis, 101
avoiding double-barreled questions, 102
avoiding negative questions, 102–103
input, 101
language, 102
software programmes, 105–106
structuring, 103
raclopride, 236
random error, 311
random sampling, 312
random-effects model, 323
randomised clinical trial, 16–17
randomised content design, 47
randomised controlled trials, 45, 205–206, 362–363
Rapid Alcohol Problems Screen, 118
rapport building, 113–114
ratio measures, 174, 175–176

rational choice, 85

RDSAT, 39

ready to drink (RTD) beverages, 164, 174–175

realism, 61–62

real-time data entry programmes, 120

recall bias, 312–313

recombinant inbred (RI) strains, 252

recruitment strategy, 50–52

referral, 290

regional cerebral blood flow (rCBF), 236

regression discontinuity, 365

reinforcement, 269–270

negative, 270

positive, 269

schedule of, 270–271

reinstatement, 275, 275

relational autonomy, 85

relevant harm, 88–89

relevant studies, 321

reliability, 13–15

calculation of, 14

definition of, 14b, 28t

parallel-test, 14

split-half, 14

test-re-test, 14

validity and, 15–16

reliability in addiction research, 11–24

flaws, 13b

implementation and quality control, 19, 24

measurement, 18–19

measurements, 21–24

sampling, 16–17

study design, 16–17

truth in the real world, 11–24

reliability of data, 345, 348–349

research grants, 88–89

research interviews, 112–113, 113b, 114

research questions, 16, 320

respondent-driven sampling, 35, 35f, 38t, 313

respondents, 112

retrospective cohort study, 307–308

risk ratios, 254, 309, 310

ROI, 241–244

routine data analysis, 304

saliva analysis, 151

sample bias, 312, 312–313

sample population, 28t

sample size, 37–39, 52, 311–312

sampling, 17–18, 27–40

cluster, 31–32, 33b, 38t

comparison of, 37–39

conceptual errors, 16

convenience, 33, 34b, 38t

errors, 16

in ethnographic research, 291–292

external validity, 16

internal validity, 16

non-probability, 27, 32

probability, 27

qualitative, 27, 36–37, 38t

respondent-driven, 35, 35f, 38t

selecting, 37

simple random, 29–30, 30b, 38t

snowball, 33–34, 34f, 38t

stratified random, 30–31, 32b, 38t

systematic, 30, 31b, 38t

targeted, 36, 36f, 38t

technical considerations, 37–40

calendar-assisted surveys, 39

Internet-based surveys, 39

sample size, 37–39

technological assistance, 39

time-space, 34, 35f, 38t

types of, 27

validity of, 21b

sampling frame, 28t

sampling interval, 29t

sampling unit, 29t

sampling without replacement, 29t

SAS, 39

school surveys, 342

Scopus, 3

screening instruments, 128–130

alcohol use disorders identification test, 128

CAGE, 128–129

Drug Abuse Screening Test, 129

Michigan Alcohol Screening Test, 129–130

Screening and brief interventions (SBI), 209, 327, 329

screening interview, 118

secondary data analysis, 304

second-order schedules, 273

sedatives, self-administration of, 230b

seed, 29t

segregation analysis, 255

selection bias, 29t

selective coding, 73, 294

self-administration. See drug self-administration

self-reported data, 110–111

self-stimulation, intracranial, 276–278

semi-structured interviews, 65, 104, 116

serotonin, 226b

Severity of Alcohol Dependence Questionnaire (SADQ), 138

Severity of Dependence Scale (SDS), 137

Short Alcohol Dependence Data (SADD), 135–136

sialic acid, 155

significance testing, 175–176

simple random sampling (SRS), 29–30, 30b, 38t

simulation studies, 203

sin taxes, 355–356

single nucleotide polymorphisms (SNPs), 256

single photon emission computed tomography, 235–236, 237t

skew, 168–169

smoking, 302b

smoking cessation studies, 45b, 52b

snowball sampling, 33–34, 34f, 38t

social constructions, 59

Social Functioning 12 (SF 12), 142

split-half reliability, 14

SPSS (Statistical Package for the Social Sciences), 39, 106, 166
<table>
<thead>
<tr>
<th>Term</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>standard deviation</td>
<td>168</td>
</tr>
<tr>
<td>standard error</td>
<td>29t</td>
</tr>
<tr>
<td>standardised interviews</td>
<td>104</td>
</tr>
<tr>
<td>standardised mean difference</td>
<td>321–322</td>
</tr>
<tr>
<td>STATA</td>
<td>39</td>
</tr>
<tr>
<td>State Trait Anxiety Index Inventory (STAI)</td>
<td>142–143</td>
</tr>
<tr>
<td>statistical analyses</td>
<td>55–56, 240</td>
</tr>
<tr>
<td>statistical packages</td>
<td>166</td>
</tr>
<tr>
<td>stepped wedge design</td>
<td>46</td>
</tr>
<tr>
<td>strata</td>
<td>30–31, 32b, 38t</td>
</tr>
<tr>
<td>stratified random sampling</td>
<td>117—118</td>
</tr>
<tr>
<td>street interviews</td>
<td>117 —118</td>
</tr>
<tr>
<td>stress-induced reinstatement</td>
<td>275</td>
</tr>
<tr>
<td>Structural Clinical Interview for the DSM</td>
<td>118</td>
</tr>
<tr>
<td>structural magnetic resonance imaging</td>
<td>237–239</td>
</tr>
<tr>
<td>structure</td>
<td>73</td>
</tr>
<tr>
<td>structured interviews</td>
<td>64–65</td>
</tr>
<tr>
<td>study designs</td>
<td>16–17</td>
</tr>
<tr>
<td>case-control studies</td>
<td>16</td>
</tr>
<tr>
<td>cohort studies</td>
<td>16–17</td>
</tr>
<tr>
<td>cross-sectional studies</td>
<td>16</td>
</tr>
<tr>
<td>observational studies</td>
<td>16</td>
</tr>
<tr>
<td>randomised clinical trial</td>
<td>16–17</td>
</tr>
<tr>
<td>research question</td>
<td>16</td>
</tr>
<tr>
<td>selection of</td>
<td>8, 16–17</td>
</tr>
<tr>
<td>validity of</td>
<td>21b</td>
</tr>
<tr>
<td>subject payment</td>
<td>84–85</td>
</tr>
<tr>
<td>substance abuse</td>
<td></td>
</tr>
<tr>
<td>biomarkers</td>
<td>147–148</td>
</tr>
<tr>
<td>frequency of</td>
<td>130–132</td>
</tr>
<tr>
<td>interviews</td>
<td>118</td>
</tr>
<tr>
<td>substantive theory</td>
<td>72–73</td>
</tr>
<tr>
<td>SUDAAN</td>
<td>39</td>
</tr>
<tr>
<td>supernormals</td>
<td>259</td>
</tr>
<tr>
<td>survey research</td>
<td>97–100</td>
</tr>
<tr>
<td>advantages of</td>
<td>99</td>
</tr>
<tr>
<td>cohort studies</td>
<td>99</td>
</tr>
<tr>
<td>data collection modes</td>
<td>100</td>
</tr>
<tr>
<td>design description</td>
<td>98–99</td>
</tr>
<tr>
<td>email surveys</td>
<td>100</td>
</tr>
<tr>
<td>history</td>
<td>97–98</td>
</tr>
<tr>
<td>internet surveys</td>
<td>100</td>
</tr>
<tr>
<td>interview types</td>
<td>104–105</td>
</tr>
<tr>
<td>issues</td>
<td>106</td>
</tr>
<tr>
<td>limitations of</td>
<td>99–100</td>
</tr>
<tr>
<td>longitudinal surveys</td>
<td>99</td>
</tr>
<tr>
<td>overview</td>
<td>97</td>
</tr>
<tr>
<td>panel studies</td>
<td>99</td>
</tr>
<tr>
<td>purposes of</td>
<td>98</td>
</tr>
<tr>
<td>trend studies</td>
<td>99</td>
</tr>
<tr>
<td>sweat analysis</td>
<td>151</td>
</tr>
<tr>
<td>sweat patches</td>
<td>151</td>
</tr>
<tr>
<td>Swedish adoption study</td>
<td>256b</td>
</tr>
<tr>
<td>systematic error</td>
<td>312</td>
</tr>
<tr>
<td>systematic sampling</td>
<td>30, 31b, 38t</td>
</tr>
<tr>
<td>taped interviews</td>
<td>120</td>
</tr>
<tr>
<td>target population</td>
<td>29t, 50–52</td>
</tr>
<tr>
<td>targeted sampling</td>
<td>36, 36f, 38t</td>
</tr>
<tr>
<td>technology transfer</td>
<td>194</td>
</tr>
<tr>
<td>telephone interviews</td>
<td>117</td>
</tr>
<tr>
<td>terminology</td>
<td>6</td>
</tr>
<tr>
<td>test-re-test reliability</td>
<td>14</td>
</tr>
<tr>
<td>tetrahydrocannabinol (THC)</td>
<td>152</td>
</tr>
<tr>
<td>thymine</td>
<td>249</td>
</tr>
<tr>
<td>Timeline Follow-Back Method (TFBM)</td>
<td>132</td>
</tr>
<tr>
<td>timeliness of data</td>
<td>345–346</td>
</tr>
<tr>
<td>time-space sampling</td>
<td>34, 35f, 38t</td>
</tr>
<tr>
<td>tobacco excise taxes</td>
<td>355–356</td>
</tr>
<tr>
<td>trait loci</td>
<td>258</td>
</tr>
<tr>
<td>transgenic animals</td>
<td>253–254</td>
</tr>
<tr>
<td>translational research</td>
<td>202–203</td>
</tr>
<tr>
<td>treatment and health data</td>
<td>343</td>
</tr>
<tr>
<td>Treatment Effectiveness</td>
<td>196b</td>
</tr>
<tr>
<td>trend studies</td>
<td>99</td>
</tr>
<tr>
<td>triangulation</td>
<td>294, 347–348</td>
</tr>
<tr>
<td>trim and fill method</td>
<td>326</td>
</tr>
<tr>
<td>true score</td>
<td>12</td>
</tr>
<tr>
<td>TWEAK</td>
<td>118</td>
</tr>
<tr>
<td>twin studies</td>
<td>235</td>
</tr>
<tr>
<td>typical case sampling</td>
<td>37</td>
</tr>
<tr>
<td>universal values</td>
<td>81b</td>
</tr>
<tr>
<td>unstructured interviews</td>
<td>104, 116</td>
</tr>
<tr>
<td>urine analysis</td>
<td>151</td>
</tr>
<tr>
<td>urine screening</td>
<td>148</td>
</tr>
<tr>
<td>U.S. Department of Agriculture</td>
<td>203</td>
</tr>
<tr>
<td>validity</td>
<td>15</td>
</tr>
<tr>
<td>concurrent</td>
<td>15</td>
</tr>
<tr>
<td>construct</td>
<td>15, 349</td>
</tr>
<tr>
<td>content</td>
<td>15</td>
</tr>
<tr>
<td>convergent</td>
<td>15, 349</td>
</tr>
<tr>
<td>criterion-related</td>
<td>15</td>
</tr>
<tr>
<td>definition of</td>
<td>14b, 29t</td>
</tr>
<tr>
<td>discriminant</td>
<td>15</td>
</tr>
<tr>
<td>of drug monitoring</td>
<td>348–349</td>
</tr>
<tr>
<td>external</td>
<td>16, 349</td>
</tr>
<tr>
<td>internal</td>
<td>16, 349</td>
</tr>
<tr>
<td>predictive</td>
<td>15</td>
</tr>
<tr>
<td>reliability and</td>
<td>15–16</td>
</tr>
<tr>
<td>validity in addiction research</td>
<td>11–24</td>
</tr>
<tr>
<td>flaws</td>
<td>13b</td>
</tr>
<tr>
<td>implementation and quality control</td>
<td>19, 24</td>
</tr>
<tr>
<td>measurements</td>
<td>18–19, 21–24</td>
</tr>
<tr>
<td>sampling</td>
<td>16–17</td>
</tr>
<tr>
<td>study design</td>
<td>16–17</td>
</tr>
<tr>
<td>truth in the real world</td>
<td>11–24</td>
</tr>
<tr>
<td>variance</td>
<td>29t, 168</td>
</tr>
<tr>
<td>violent crimes</td>
<td>359b</td>
</tr>
<tr>
<td>visual data</td>
<td>68–69</td>
</tr>
<tr>
<td>voluntary participation</td>
<td>79</td>
</tr>
<tr>
<td>voxel-by-voxel method</td>
<td>241–244</td>
</tr>
<tr>
<td>Waddington, Conrad Hal</td>
<td>261</td>
</tr>
<tr>
<td>Watson, James</td>
<td>249, 251f, 252b</td>
</tr>
<tr>
<td>Web of Science</td>
<td>3</td>
</tr>
<tr>
<td>weighting</td>
<td>29t</td>
</tr>
<tr>
<td>Wilkins, Maurice</td>
<td>252b</td>
</tr>
<tr>
<td>withdrawal syndromes</td>
<td>231–232</td>
</tr>
<tr>
<td>within-subject designs</td>
<td>47–48</td>
</tr>
<tr>
<td>World Health Organization</td>
<td>6</td>
</tr>
<tr>
<td>Worldwide Political Abstracts</td>
<td>3</td>
</tr>
</tbody>
</table>